Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

283.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
52 53 Next >
Death Cross Looms Over Amgen Investors
Via Benzinga
7 Over-$100 Stocks That Are Worth Every Penny
To get most of the best-known stocks, you have to be prepared to pay at least $100 per share. Here are seven stocks to buy. 
Via InvestorPlace
Could This Humira Biosimilar Be a Winner for Amgen?
This Humira biosimilar just launched in the U.S. several weeks ago. 
Via The Motley Fool
A Look Into Amgen's Debt
Shares of Amgen Inc. (NASDAQ:AMGN) fell by 17.83% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials. 
Via Benzinga
3 Value Stocks You'll Regret Not Buying on the Dip
These three undervalued healthcare stocks are solid picks for patient investors. 
Via The Motley Fool
Is Amazon a Blue Chip Stock?
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat. 
Via MarketBeat
Want Growing Passive Income? Buy This Dow Jones Stock
This big pharma company possesses a solid drug pipeline. 
Via The Motley Fool
Amgen Nearing Buy Point With Great Dividend and Fundamentals
Amgen Inc. (NASDAQ: AMGN) is right near the bottom of a more than 6-year trend channel.  
Via Benzinga
Want More Reliable Dividend Income? Buy This Dividend King.
This big pharma company possesses a deep drug portfolio and pipeline. 
Via The Motley Fool
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
AMGN Near Buy Point With Strong Fundamentals And Rising Dividend
AMGN is a steady long-term performer and offers a nice upside for a several-month trade or longer. 
Via Talk Markets
Devon Energy, Broadcom, Amgen And This Company Report Earnings Next Week: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Requisite Capital Management's Bryn Talkington praised Devon Energy Corporation (NYSE: DVN) for its free cash flow. 
Via Benzinga
Is This the Start of a Nightmare for AbbVie Stock?
With a competitor set to devour market share, stormy waters might be ahead. 
Via The Motley Fool
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Market-Beating Dividend Stocks to Buy With $500
These two leading healthcare stocks have been rewarding shareholders with dividends for a while. 
Via The Motley Fool
Why Billionaires Paul Tudor Jones and George Soros Bought Up Horizon (HZNP) Stock
Two well-regarded billionaire investors -- George Soros and Paul Tudor Jones -- bought Horizon (HZNP) stock last quarter. 
Via InvestorPlace
Billionaires Loaded Up on These 3 Stocks in the Fourth Quarter of 2022
Billionaire-led investing firms scooped up shares of Paramount Global, Bank of America, and Horizon Therapeutics in Q4. 
Via The Motley Fool
Tuesday Talk: My Sweet CPI
The street is hoping for sweet January CPI data today and that anticipation pushed stocks higher on Monday. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
Top 5 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected
The company expects Humira sales to fall 37% this year. 
Via Investor's Business Daily
AbbVie Profit Outlook Widely Misses As The U.S. Humira Battle Kicks Off
The company's fourth quarter also came in mixed with lighter-than-expected sales. 
Via Investor's Business Daily
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years. 
Via The Motley Fool
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?
Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
The 7 Most Undervalued Dow Stocks to Buy in February 2023
If you’re looking for the best deals among the most iconic enterprises, these are the most undervalued Dow stocks to buy. 
Via InvestorPlace
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.